Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02296242 |
Recruitment Status :
Completed
First Posted : November 20, 2014
Results First Posted : September 5, 2018
Last Update Posted : January 29, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acute Myelogenous Leukemia Myelodysplastic Syndrome | Drug: BVD-523 | Phase 1 Phase 2 |
The study is being performed to assess the safety and tolerability of BVD-523 given orally, twice daily for 21-day cycles.
Part 1 of the study will establish dose limiting toxicities (DLT), maximum tolerated dose (MTD), and the recommended Phase 2 dose (RP2D).
In Part 2 of the study, additional patients with particular tumor types and/or cancers harboring specific genetic mutations will be recruited for treatment at the Recommended Phase 2 Dose (RP2D). Patients may also be assessed pharmacodynamic measures in healthy or malignant tissues, using biomarker assays for phosphorylation, cytotoxic or cytostatic measures.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 53 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase 1/2 Dose-Escalation, Safety, Clinical Activity, Pharmacokinetic and Pharmacodynamic Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes |
Study Start Date : | November 2014 |
Actual Primary Completion Date : | June 15, 2017 |
Actual Study Completion Date : | June 15, 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: BVD-523 |
Drug: BVD-523
Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle |
- Number of Patients With Dose Limiting Toxicities [ Time Frame: In the first 21 days of treatment ]DLT defined using CTCAE v.4.03. All toxicities were considered to be related to BVD523 if not definitively explained by underlying disease, intercurrent illness, or con meds.
- Steady-state Plasma Concentration of BVD-523 and Selected Metabolites Over 12 Hours [ Time Frame: Samples will be collected on or about Day 22 of the protocol ]The PK population consisted of patients who received at least one dose of BVD-523 and had evaluable PK data in plasma.
- Clinical Evidence of Cancer Response in Bone Marrow Biopsies [ Time Frame: Until patient discontinuation; ~24 months on average ]Assessments were made via bone marrow biopsies using the International Working Group 2003 and 2006 criteria for AML or MDS, respectively. Bone marrow assessments (aspiration or biopsy, cytogenetics) were collected prior to therapy on Day 1 and Day 22, every 2 cycles thereafter, as well as at the final study visit if discontinuation was not due to disease progression. Some patients were unable to have bone marrow assessments taken at any or all of the time points. Shown is best response across all time points. Less than partial remission/response (<PR), partial remission/response (PR), complete remission/response with incomplete platelet recovery (CRp), or complete remission/response (CR).
- Duration of Disease Control in Patients That Respond [ Time Frame: Until patient discontinuation; ~24 months on average ]Assessments were made via bone marrow biopsies using the International Working Group 2003 and 2006 criteria for AML or MDS, respectively. Progression-free survival (PFS) and duration of response (DOR) of AML or MDS patients was assessed in patients treated with BVD-523 that achieved complete remission/response (CR) or complete remission/response with incomplete platelet recovery (CRp). <PR = less than partial remission/response. Shown is the duration (number of days) of CR or CRp response for the 2 patients in part 2 that obtained this level of response.
- Pharmacodynamic Results of Inhibition (%) of Molecular Target (ERK Pathway) Assessed by Blood and Tissue Analyses. [ Time Frame: Patients will be evaluated at baseline and on or about Day 22 of the protocol ]Multiple biomarkers intended to demonstrate inhibition of the molecular target, and mechanism of action were investigated from blood and/or bone marrow aspirate samples. Phosphorylation of ERK enzyme substrate proteins (e.g. RSK1 and RSK2 genes) were measured. Additional biomarkers, including PBMCs and/or DNA sequence analysis, were identified and measured as appropriate. Measurements were by ELISA. The pharmacodynamics (PD) population was defined as all patients who received at least one dose of study drug and had sufficient, valid PD samples to estimate key parameters for at least one of the days of sampling.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 100 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Have either of the following diagnoses:
- Morphologically confirmed acute myeloid leukemia (AML), except acute promyelocytic leukemia (APL), including leukemia secondary to prior therapy or antecedent hematologic disorder (e.g., MDS or myeloproliferative disorders), who have failed to achieve CR or who have relapsed after prior therapy and are not candidates for potentially curative therapy
- Intermediate-2 or High-grade risk MDS (including chronic myelomonocytic leukemia (CMML))
- Have received at least one prior therapy. Patients who are over age 65 and have not received therapy for AML are also eligible, if they are not candidates for induction chemotherapy
- ECOG performance status of 0 to 2
- Predicted life expectancy of ≥ 3 months
- Adequate liver, renal and cardiac function
For Group 1 in Part 2 of the Study ONLY:
• Positive for RAS mutation at a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory prior to study entry
Exclusion Criteria:
- Concomitant malignancies except carcinoma in situ, basal or squamous cell skin carcinoma; low grade prostate cancer treated with prostatectomy more than 10 years ago; early stage melanoma treated with complete surgical excision more than 5 years ago; carcinoma in situ of cervix treated with cone procedure more than 8 years ago
- Gastrointestinal condition which could impair absorption of study medication
- Uncontrolled or severe intercurrent medical condition
- Patients with rapidly increasing peripheral blood blast counts
- Known uncontrolled central nervous system involvement
- Any cancer-directed therapy within 28 days or 5 half-lives, whichever is shorter
- Any concurrent or prior use of an investigational drug (including MEK inhibitors) within previous 28 days or 5 half-lives, whichever is shorter
- Received chemotherapy regimens with delayed toxicity within the last four weeks (six weeks for prior nitrosourea or mitomycin C). Received chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last two weeks.
- Ongoing anticoagulant therapy that cannot be held if necessary to permit bone marrow sampling.
- Major surgery within 4 weeks prior to first dose
- Pregnant or breast-feeding women
- Any evidence of serious active infections
- Any important medical illness or abnormal laboratory finding that would increase the risk of participating in this study
- A history or current evidence/risk of retinal vein occlusion or central serous retinopathy
- Concurrent therapy with drugs known to be strong inhibitors of CYP1A2, CYP2D6, and CYP3A4, or strong inducers of CYP3A4

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02296242
United States, California | |
UCLA Medical Center | |
Los Angeles, California, United States, 90024 | |
United States, Georgia | |
Winship Cancer Institute of Emory University | |
Atlanta, Georgia, United States, 30322 | |
United States, New York | |
Roswell Park Cancer Institute | |
Buffalo, New York, United States, 14263 | |
United States, Pennsylvania | |
Perelman Center for Advanced Medicine | |
Philadelphia, Pennsylvania, United States, 19104 | |
United States, Texas | |
MD Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Documents provided by BioMed Valley Discoveries, Inc:
Responsible Party: | BioMed Valley Discoveries, Inc |
ClinicalTrials.gov Identifier: | NCT02296242 |
Other Study ID Numbers: |
BVD-523-02 BVD-523-02 ( Other Identifier: BioMed Valley Discoveries, Inc. ) |
First Posted: | November 20, 2014 Key Record Dates |
Results First Posted: | September 5, 2018 |
Last Update Posted: | January 29, 2019 |
Last Verified: | January 2019 |
Leukemia Preleukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Myelodysplastic Syndromes Syndrome Disease |
Pathologic Processes Neoplasms by Histologic Type Neoplasms Bone Marrow Diseases Hematologic Diseases Precancerous Conditions |